Reducing residual cardiovascular risk: The relevance of raising high-density lipoprotein cholesterol in patients on cholesterol-lowering treatment

Diabetes and Vascular Disease Research

Volumn 3, Issue SUPPL. 2, 2006, Pages

  Pedersen, Terje R ^a,g   Assmann, Gerd ^b   Bassand, Jean Pierre ^c   Chapman, M John ^d   Erbel, Raimund ^e   Sirtori, Cesare ^f  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f UNIVERSITY OF MILAN   (Italy)

^g ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL METABOLISM; CLINICAL TRIAL; DRUG TOLERABILITY; DYSLIPIDEMIA; FLUSHING; HUMAN; META ANALYSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 33750321314     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2006.011     Document Type: Review

References (89)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
2. International Atherosclerosis Society. Harmonized clinical guidelines on prevention of atherosclerotic vascular disease. http://www.athero.org.
3. [Integrating the guidelines of the International Task Force for Prevention of Coronary Heart Disease, http://www.chd-taskforce.de/guidelines/ toc.htm and the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)]. Accessed 25 Feb 2006.
4. De Backer G, Ambrosioni E, Borch-Johnsen K et al. Executive summary. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601-10.
5. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
6. La Rosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials. JAMA 1999;282:2340-6.
7. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
8. LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
9. Pedersen TR, Faergeman O, Kastelein JJP et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL Study: a randomized controlled trial. JAMA 2005;294:2437-45.
10. Davidson MH, Toth PP. Comparative effects of lipid-lowering therapies. Progr Cardiovasc Dis 2004;47:73-104.
11. Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 2003;92:152-60.
12. Balk EM, Lau J, Goudas C et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease. A systematic review. Ann Intern Med 2003;139:670-82.
13. Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA 2006;295:1556-65.
14. Carroll MD, Lacher DA, Sorlie PD et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 2005;294:1773-81.
15. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
16. The Pan-Asian Consensus Panel on HDL-C. Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: an Asian/Pacific consensus. Br J Diabetes Vasc Dis 2005;5 (suppl 2):S1-S16.
17. Waldius G, Jungner I, Holme I et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-33.
18. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.
19. Walldius G, Aastveit AH, Jungner I. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Intern Med 2006;259:259-66.
20. Gordon T, Castelli WP, Hjortland MC et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14.
21. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the PROCAM Study. Circulation 2002;105:310-15.
22. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15.
23. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death. The Framingham Study. Arch Intern Med 1981;141:1128-31.
24. Koro CE, Bowlin SJ, Stump TE et al. The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events. Am Heart J 2006;151:755.e1-755.e6.
25. Barter PJ, Rye K-A. High density lipoproteins and coronary heart disease. Atherosclerosis 1996;121:1-12.
26. Barter PJ, Nicholls S, Rye K-A et al. Antiinflammatory properties of HDL. Circ Res 2004;95:764-72.
27. Assman G, Nofer J-R. Atheroprotective effects of high density lipoproteins. Ann Rev Med 2003;54:321-41.
28. Nofer J-R, Kehrel B, Fobker M et al. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 2002;161:1-16.
29. Calabresi L, Gomaraschi M, Franceschini C. Endothelial protection by high density lipoproteins. Arterioscler Thromb Vasc Biol 2003;23: 1724-31.
30. Von Birgelen C, Hartmann M, Mintz GS et al. Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed by serial long-term (≥ 12 months) follow-up intravascular ultrasound. Circulation 2003;108: 2757-62.
31. Von Birgelen C, Hartmann M, Mintz GS et al. Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries. Circulation 2004;110:1579-85.
32. Nissen SE, Tsunoda T, Tuzcu EM et al. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. A randomized controlled trial. JAMA 2003;290:2292-300.
33. Johnsen SH, Mathiesen EB, Fosse E et al. Elevated high-density lipoprotein cholesterol levels are protective against plaque progression. A follow-up study of 1952 persons with carotid atherosclerosis. The Tromsø study. Circulation 2005;112:498-504.
34. Chapman MJ, Assmann G, Fruchart J-C, Shepherd J, Sirtori C on behalf of the European Consensus Panel on HDL-C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004;20:1253-68.
35. Coronary Drug Project Research Croup. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.
36. Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55.
37. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-18.
38. Robins SJ, Collins D, Wittes JT et al. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial. JAMA 2001;285:1585-91.
39. Bruckert E, Baccara-Dinet M, McCoy F, Chapman J. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin 2005;21:1927-34.
40. Wei L, Murphy MJ, MacDonald TM. Impact on cardiovascular events of increasing high density lipoprotein cholesterol with and without lipid lowering drugs. Heart 2006;92:746-51.
41. Nissen SE, Tuzcu EM, Schoenhagen P et al. Stalin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38.
42. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223:405-18.
43. Whitney EJ, Krasuski RA, Personius BE et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005;142:95-104.
44. Rosenson R. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy. Am Heart J 2006;151:556-63.
45. Sacks FM, Tonkin AM, Shepherd J et al. The effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. Circulation 2000;102:1893-900.
46. Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.
47. Taylor AJ, Sullenberger LE, Lee HJ et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-17.
48. Greenland P, Abrams J, Aurigemma GP et al. AHA Scientific Statement. Prevention Conference V. Beyond secondary prevention: identifying the high-risk patient for primary prevention: non-invasive tests of atherosclerotic burden: Writing Group III. Circulation 2000;101:e16-e22.
49. Taylor AJ, Sullenberger LE, Lee HY. ARBITER 3: Atherosclerosis regression during open-label continuation of extended-release niacin following ARBITER 2. Circulation 2005;112(17)suppl 11:11-179(abstract 943).
50. Moffatt RJ, Chelland SA, Pecott DL, Stamford BA. Acute exposure to environmental tobacco smoke reduces HDL-C and HDL2-C. Prev Med 2000;38:637-41.
51. Kelley GA, Kelley KS, Tran ZV. Walking, lipids, and lipoproteins: a meta-analysis of randomized controlled trials. Prev Med 2004;38:651-61.
52. Rimm EB, Williams P, Fosher K et al. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ 1999;319:1523-8.
53. Van Gaal LF, Wauters MA, De Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 1997;21(suppl 1):S5-S9.
54. Harper CR, Jacobson TA. Usefulness of omega-3 fatty acids and the prevention of coronary heart disease. Am J Cardiol 2005;96:1521-9.
55. Belalcazar LM, Ballantyne CM. Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol. Prog Cardiovasc Dis 1998;41:151-74.
56. Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003;171:1-13.
57. Steiner G. Fibrates and coronary risk reduction. Atherosclerosis 2005; 182:199-207.
58. Birjmohun RS, Hutten BA, Kastelein JJP, Stroes ESG. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. A meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005;45: 185-97.
59. Athyros VG, Papageorgiou A, Athyrou W et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002;25:1198-202.
60. Grundy SM, Vega GL, Yuan Z et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005;95:462-8.
61. Durrington PN, Tuomilehto J, Hamann A et al. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidemia. Diabetes Res Clin Pract 2004;64:137-51.
62. Wierzbicki AS, Mikhailidis DP, Wray R et al. Statin-fibrate combination therapy for hyperlipidaemia: a review. Curr Med Res Opin 2003;19: 155-68.
63. Keech A, Simes RJ, Barter P et al. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849-61.
64. Ellen RL, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 1998;81:60B-65B.
65. De la Serna G, Cadarso C. Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia. Clin Pharmacol Ther 1999;66:166-72.
66. Colhoun H. After FIELD: should fibrates be used to prevent cardiovascular cular disease in diabetes? Lancet 2005;366:1829-31.
67. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Available from www.accordtrial.org, accessed 13 February 2006.
68. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005;258:94-114.
69. McCormack PL, Keating CM. Prolonged-release nicotinic acid. A review of its use in the treatment of dyslipidaemia. Drugs 2005;65: 2719-40.
70. Morgan JM, Capuzzi DM, Guyton JR et al. Treatment effect of NIAS-PAN, a controlled-release nicotinic acid, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther 1996;1:195-202.
71. Goldberg A, Alagona P Jr, Capuzzi DM et al. Multiple-dose efficacy and safety of an extended-release form of nicotinic acid in the management of hyperlipidemia. Am J Cardiol 2000;85:1100-05.
72. Shepherd J, Betteridge J, Van Gaal L on behalf of a European Consensus Panel. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome. A position paper developed by a European Consensus Panel. Curr Med Res Opin 2005;21:665-82.
73. Knopp RH, Alagona P, Davidson M et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998;47:1097-104.
74. HPS2-THRIVE study. Available from http://www.ctsu.ox.ac.uk/news/ hps2_thrive.htm (Accessed 26 June 2006).
75. McGovern ME. Use of nicotinic acid in patients with elevated fasting glucose, diabetes, or metabolic syndrome. Br J Diabetes Vasc Dis 2004; 4:78-85.
76. Kashyap ML, McGovern ME, Berra K et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002;89:672-8.
77. Bays HE, Dujovne CA, McGovern ME et al. Comparison of once-daily niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin [the Advicor Versus Other Cholesterol-modulating Agents Trial Evaluation (ADVOCATE)]. Am J Cardiol 2003;91:667-72.
78. Capuzzi DM, Morgan JM, Weiss RJ et al. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol 2003;91:1304-10.
79. Hunninghake DB, McGovern ME, Koren M et al. A dose-ranging study of a new, once daily dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol 2003;26:112-18.
80. Insull Jr W, McGovern ME, Schrott H et al. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Arch Intern Med 2004; 164:1121-17.
81. Clinical Trial: AIM HIGH: Niacin plus statin to prevent vascular events. Available from www.clinicaltrials.gov.ct/show/NCT00120289. Accessed 13 Feb 2006.
82. De Grooth CT, Kuivenhoven JA, Stalenhoef AFH et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans. Circulation 2002;105:2159-65.
83. Clark RW, Sutfin TA, Ruggeri RB et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein. An initial multidose study of torcetrapib. Arterioscler Thromh Vasc Biol 2004;24:490-7.
84. Brousseau ME, Schaefer EJ, Wolfe ML et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004;350:1505-15.
85. Brewer HB. Increasing HDL cholesterol levels. N Engl J Med 2004; 350:1491-4.
86. De Grooth GJ, Klerkx AH, Stroes ES et al. A review of CETP and its relation to atherosclerosis. J Lipid Res 2004;45:1967-74.
87. Tonstad S. Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors. Nutr Metab Cardiovasc Dis 2006;16:156-62.
88. Wierzbicki AS. Lipid-altering drugs: the future. Int J Clin Pract 2004;58: 1063-72.
89. Chapman MJ. Therapeutic elevation of HDL cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacology and Therapeutics 2006;111:893-908.